相关实验视频

Updated: Jun 26, 2025

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Published on: July 18, 2017

与糖共运输体-2 抑制剂相关的生殖尿路感染性不良事件:一个网络元分析和元回归

Kannan Sridharan¹, Gowri Sivaramakrishnan²

¹Department of Pharmacology & Therapeutics, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.

Expert review of clinical pharmacology

|May 11, 2024

概括

糖携运输体-2 抑制剂 (SGLT2is) 增加尿路感染 (UTI) 和生殖器感染 (GI) 的风险. 建议对高风险人群采取预防措施,例如那些BMI为30 kg/m2或更高的人.

科学领域:

药理学药理学是指药理学的学科.
传染性疾病传染性疾病
临床医学临床医学

背景情况:

糖共传递剂-2 抑制剂 (SGLT2is) 是一种广泛使用的药物类别.
有关SGLT2is带来的尿路感染 (UTI) 和生殖器感染 (GI) 风险的证据是相互矛盾的.
这项研究通过网络元分析和元回归来解决了这一争议.

研究的目的:

进行网络元分析和元回归,以评估与SGLT2抑制剂相关的尿路感染和胃肠道感染风险.
确定导致这些感染的风险因素.
估计需要伤害的数量 (NNH) 对于尿道感染和肠道感染.

主要方法:

一个网络对涉及SGLT2抑制剂的随机对照试验 (RCT) 的元分析和元回归.
包括报告尿路感染和胃肠道感染发生率的研究.
使用95%置信区间 (95% CI) 计算赔率比率 (OR) 并估计NNH.

主要成果:

与SGLT2is.一起观察到尿路感染 (OR: 1.11; 95% CI: 1.06, 1.16) 和GI (OR: 3.5; 95% CI: 3.1, 3.9) 的风险增加.
男性的尿道感染和肠道感染风险较低.
较高的BMI (≥30 kg/m2) 和较长的治疗持续时间 (≥6个月) 被确定为危险因素. 尿路感染的NNH为16,肠道感染的NNH为25.

结论:

SGLT2 抑制剂与尿路感染和肠道感染的风险增加有关.
这些发现应纳入临床指南.
对于高风险患者群体,建议特别谨慎和采取预防措施.

关键词:

在Canagliflozin中使用.图形用户界面 (GUI) 是一个这就是SGLT2i.这是一个UTI,UTI是UTI.达帕格利弗洛辛 (Dapagliflozin) 是一种艾姆帕格利夫洛辛 (Empagliflozin) 是一种生殖器感染生殖器感染

更多相关视频

Establishment and Characterization of UTI and CAUTI in a Mouse Model

Establishment and Characterization of UTI and CAUTI in a Mouse Model

Published on: June 23, 2015

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

相关概念视频

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Secondary Active Transport

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...